Interestingly, and in line with the previous observation, the difference observed in the expression levels of SRSF6 between both cohorts of GHomas (i.e., upregulated in the Spanish cohort and no change in the Brazilian cohort) could be due to the fact that the patients from Spain, but not from Brazil, were pre-treated with somatostatin analogues before surgery, which has been shown to alter the expression pattern of key receptors in pituitary tumor samples [64]. This evidence concerns the gene SRSF6 and pituitary tumor.